Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group
International Journal of Technology Assessment in Health Care · 2023 · 39 (1)
DOI: 10.1017/s0266462323000375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Technology Assessment in Health Care, online erschienen am 16.06.2023. Verfasst von Milou Amber Hogervorst und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Ne…. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Policy Making. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface.
Methods
Six online discussions among WG members (Dec 2021–Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions.
Results
The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: “unavailable,” “inaccurate,” “conflicting,” “not understandable,” “random variation,” “information,” “prediction,” “impact,” “risk,” “relevance,” “context,” and “judgment.” These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed.
Conclusions
The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
- National Health Care Institute (ZIN), Diemen, The Netherlands.
- Global Regulatory Policy, MSD, Copenhagen, Denmark.
- Global Pricing & Market Access, GSK, Philadelphia, PA, USA.
- Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, Spain.
- Basque Office for Health Technology Assessment, Osteba, Barakaldo, Spain.
ORCID-Profile: Milou Amber Hogervorst, Rick Vreman, Inkatuuli Heikkinen, Inaki Gutierrez-Ibarluzea, Hans-Georg Eichler, Elena Petelos, Wim Goettsch, Wija Oortwijn
Zitieren
APA
Hogervorst, M. A., Vreman, R., Heikkinen, I., Bagchi, I., Gutierrez-Ibarluzea, I., Ryll, B., Eichler, H. G., Petelos, E., Tunis, S., Sapede, C., Goettsch, W., Janssens, R., Huys, I., Barbier, L., DeJean, D., Strammiello, V., Lingri, D., Goodall, M., Papadaki, M., …, & Oortwijn, W. (2023). Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group. International Journal of Technology Assessment in Health Care, 39(1). https://doi.org/10.1017/s0266462323000375
Vancouver
Hogervorst MA, Vreman R, Heikkinen I, Bagchi I, Gutierrez-Ibarluzea I, Ryll B, et al. Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group. International Journal of Technology Assessment in Health Care. 2023;39(1). doi:10.1017/s0266462323000375
BibTeX
@article{Hogervorst2023,
author = {Hogervorst, Milou Amber and Vreman, Rick and Heikkinen, Inkatuuli and Bagchi, Indranil and Gutierrez-Ibarluzea, Inaki and Ryll, Bettina and Eichler, Hans-Georg and Petelos, Elena and Tunis, Sean and Sapede, Claudine and Goettsch, Wim and Janssens, Rosanne and Huys, Isabelle and Barbier, Liese and DeJean, Deirdre and Strammiello, Valentina and Lingri, Dimitra and Goodall, Melinda and Papadaki, Magdalini and Toussi, Massoud and Voulgaraki, Despina and Mitan, Ania and Oortwijn, Wija},
title = {Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group},
journal = {International Journal of Technology Assessment in Health Care},
year = {2023},
volume = {39},
number = {1},
doi = {10.1017/s0266462323000375}
}
EUVIMED